Monopar Therapeutics (NASDAQ:MNPR) Trading Down 3.9% – Time to Sell?

Monopar Therapeutics Inc. (NASDAQ:MNPR) shares dropped 3.9% on Friday . The stock traded as low as $106.50 and last traded at $106.55. Approximately 64,031 shares changed hands during mid-day trading, a decline of 71% from the average daily volume of 220,969 shares. The stock had previously closed at $110.88.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the stock. HC Wainwright lifted their price target on shares of Monopar Therapeutics from $105.00 to $125.00 and gave the stock a “buy” rating in a research report on Wednesday, July 22nd. Cantor Fitzgerald downgraded Monopar Therapeutics from an “overweight” rating to a “neutral” rating and raised their price objective for the stock from $109.00 to $119.00 in a research note on Thursday, August 13th. Zacks Research lowered Monopar Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 13th. Wall Street Zen cut Monopar Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, August 16th. Finally, Barclays reissued an “overweight” rating and issued a $128.00 target price (up from $125.00) on shares of Monopar Therapeutics in a research note on Thursday, August 13th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Monopar Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $118.67.

Monopar Therapeutics Price Performance

The stock has a market cap of $722.61 million, a P/E ratio of -49.61 and a beta of 1.47. The stock’s 50 day simple moving average is $100.72 and its two-hundred day simple moving average is $72.97.

Monopar Therapeutics (NASDAQ:MNPR) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($0.62) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.64) by $0.02. As a group, analysts forecast that Monopar Therapeutics Inc. will post -2.94 earnings per share for the current fiscal year.

Institutional Trading of Monopar Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of MNPR. ADAR1 Capital Management LLC lifted its position in shares of Monopar Therapeutics by 13.0% in the first quarter. ADAR1 Capital Management LLC now owns 264,278 shares of the company’s stock worth $14,480,000 after purchasing an additional 30,370 shares in the last quarter. Bank of New York Mellon Corp grew its position in Monopar Therapeutics by 21.2% in the first quarter. Bank of New York Mellon Corp now owns 78,618 shares of the company’s stock valued at $4,307,000 after purchasing an additional 13,761 shares in the last quarter. Siren L.L.C. grew its position in Monopar Therapeutics by 27.2% in the first quarter. Siren L.L.C. now owns 270,118 shares of the company’s stock valued at $14,800,000 after purchasing an additional 57,820 shares in the last quarter. Virtu Financial LLC bought a new position in Monopar Therapeutics in the fourth quarter valued at $654,000. Finally, Walleye Capital LLC acquired a new stake in Monopar Therapeutics in the 1st quarter valued at $3,458,000. Institutional investors and hedge funds own 1.83% of the company’s stock.

Monopar Therapeutics Company Profile

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.